In the ELEONOR study, a 24-week trial conducted in 224 insulin-naïve people with poorly controlled Type 2 diabetes, the efficacy and safety of a basal-plus treatment strategy, comprising insulin glargine plus a single dose of insulin glulisine at the meal with the highest blood glucose excursion, were shown to be unaffected by two different methods of monitoring for dose adjustment, i.e. Telecare or self-monitoring of blood glucose 41. Here, INS is linked to type 2 diabetes mellitus.